The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma

Lu,Hongsheng; Yang,Zhaohui; Zhang,Hui; Gan,Meifu; Zhou,Tao; Wang,Siling

doi:10.3892/etm.2012.859

The expression and clinical significance of matrix metalloproteinase 7 and tissue inhibitor of matrix metalloproteinases 2 in clear cell renal cell carcinoma

Authors:
- Hongsheng Lu
- Zhaohui Yang
- Hui Zhang
- Meifu Gan
- Tao Zhou
- Siling Wang
View Affiliations

Affiliations: Department of Pathology, Taizhou Central Hospital of Taizhou Enze Medical Group, Taizhou 318000, P.R. China, Department of Pathology, Taizhou Hospital of Taizhou Enze Medical Group, Linhai 317000, P.R. China
Published online on: December 17, 2012 https://doi.org/10.3892/etm.2012.859
Pages: 890-896

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma (RCC) is one of the most common malignant neoplasms in the urinary system, and has a high frequency of local invasion and distant metastasis. This study assessed the expression and clinical significance of matrix metalloproteinase 7 (MMP-7) and tissue inhibitor of matrix metalloproteinases 2 (TIMP-2) in human clear cell renal cell carcinoma (CCRCC) by tissue microarray, immunohistochemistry and RT-PCR analysis. The expression of MMP-7 in CCRCC tissues was significantly higher compared with that in the control group (CG) and TIMP-2 expression in CCRCC, by contrast, was lower compared with that in the CG. The expression of MMP-7 and TIMP-2 in the CCRCC tissues was significantly correlated with the pathological grade and clinical stage. Log-rank analyses indicated that upregulation of MMP-7 and downregulation of TIMP-2 expression may occur during the progression of CCRCC, and Cox multivariate survival rate analysis demonstrated that there was also a positive correlation between the pathological grade, clinical stage, MMP-7 expression and survival rate. Thus, MMP-7 is an independent prognostic factor and MMP-7 and TIMP-2 may serve as useful molecular markers for evaluating prognosis in CCRCC patients.

View Figures

View References

1.	Awakura Y, Ito N, Nakamura E, Takahashi T, Kotani H, Mikami Y, Manabe T, Kamoto T, Habuchi T and Ogawa O: Matrix metalloproteinase-9 polymorphisms and renal cell carcinoma in a Japanese population. Cancer Lett. 241:59–63. 2006. View Article : Google Scholar : PubMed/NCBI
2.	Nagase H and Woessner JF: Matrix metalloproteinases. J Biol Chem. 274:21491–21494. 1999. View Article : Google Scholar
3.	Declerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM and Muschel RJ: Proteases, extracellular matrix and cancer: a workshop of the path B study section. Am J Pathol. 164:1131–1139. 2004. View Article : Google Scholar : PubMed/NCBI
4.	Di Nezza LA, Misajon A and Zhang J: Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer. 94:1466–1475. 2002.
5.	Egelblad M and Werb Z: New functions for the matrix metal-loproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
6.	Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD and Mansel RE: Expression of membrane type-1 matrix metal-loproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells. Int J Mol Med. 17:583–590. 2006.PubMed/NCBI
7.	Ogata Y, Miura K, Ohkita A, Nagase H and Shirouzu K: Imbalance between matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 expression by tumor cells implicated in liver metastasis from colorectal carcinoma. Kurume Med J. 48:211–218. 2001. View Article : Google Scholar
8.	Moore CS and Crocker SJ: An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol. 180:12–16. 2012. View Article : Google Scholar : PubMed/NCBI
9.	Hahne JC, Fuchs T, El Mustapha H, Okuducu AF, Bories JC and Wernert N: Expression pattern of matrix metalloproteinase and TIMP genes in fibroblasts derived from Ets-1 knock-out mice compared to wild-type mouse fibroblasts. Int J Mol Med. 18:153–159. 2006.PubMed/NCBI
10.	Abdel-Wahed MM, Asaad NY and Aleskandarany M: Expression of matrix metalloproteinase-2 in renal cell carcinoma. J Egypt Natl Canc Inst. 16:168–177. 2004.PubMed/NCBI
11.	Aoyama T, Yamamoto S, Kanematsu A, Ogawa O and Tabata Y: Local delivery of matrix metalloproteinase gene prevents the onset of renal sclerosis in streptozocin-induced diabetic mice. Tissue Eng. 9:1289–1296. 2003. View Article : Google Scholar : PubMed/NCBI
12.	Hirata H, Naito K, Yoshihiro S, Matsuyama H, Suehiro Y and Hinoda Y: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. Int J Cancer. 106:372–374. 2003. View Article : Google Scholar : PubMed/NCBI
13.	Hirata H, Okayama N, Naito K, Inoue R, Yoshihiro S, Matsuyama H, Suehiro Y, Hamanaka Y and Hinoda Y: Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal cell carcinoma. Carcinogenesis. 25:2379–2384. 2004. View Article : Google Scholar : PubMed/NCBI
14.	Huo N, Ichikawa Y and Kamiyama M: MMP-7 (matrilysin) accelerated growth of human umbilical vein endothelial cells. Cancer Lett. 177:95–100. 2002. View Article : Google Scholar : PubMed/NCBI
15.	Miyata Y, Iwata T, Maruta S, Kanda S, Nishikido M, Koga S and Kanetake H: Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role. Eur Urol. 52:791–597. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Struckmann K, Mertz KD, Steu S, Storz M, Staller P, Krek W, Schraml P and Moch H: pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J Pathol. 214:464–471. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Yang SD, Sun RC, Mu HJ, Xu ZQ and Zhou ZY: The expression and clinical significance of TGF-β1 and MMP2 in human renal clear cell carcinoma. Int J Surg Pathol. 18:85–93. 2010.
18.	Eble JN, Sauter G, Epstein JI and Sesterhenn IA: World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. IARC Press; Lyon, France: pp. 16–18. 2004
19.	Lu H, Gan M, Zhang G, Zhou T, Yan M and Wang S: Expression of survivin, caspase-3 and p53 in cervical cancer assessed by tissue microarray: correlation with clinicopathology and prognosis. Eur J Gynaecol Oncol. 6:662–666. 2010.PubMed/NCBI
20.	Johansson N, Ahonen M and Kahari VM: Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci. 57:5–15. 2000. View Article : Google Scholar
21.	Stetler-Stevenson WG, Liotta LA and Kleiner DE: Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. Faseb J. 7:1434–1441. 1993.PubMed/NCBI
22.	Stetler-Stevenson WG and Yu AE: Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol. 11:143–152. 2001. View Article : Google Scholar : PubMed/NCBI
23.	Kawata N, Nagane Y, Hirakata H, Ichinose T, Okada Y, Yamaguchi K and Takahashi S: Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma. Urology. 69:1050–1053. 2007. View Article : Google Scholar
24.	Kawata N, Nagane Y and Igarashi T: Strong significant correlation between MMP-9 and systemic symptoms in patients with localized renal cell carcinoma. Urology. 68:523–527. 2006. View Article : Google Scholar : PubMed/NCBI
25.	Miyata Y, Iwata T, Ohba K, Kanda S, Nishikido M and Kanetake H: Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis. Clin Cancer Res. 12:6998–7003. 2006. View Article : Google Scholar
26.	Kumaki F, Matsui K and Kawai T: Expression of matrix metal-loproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol. 159:2125–2135. 2001. View Article : Google Scholar